东诚药业子公司蓝纳成获得放射性药品生产许可证

Core Viewpoint - Dongcheng Pharmaceutical (002675.SZ) announced that its subsidiary, Yantai Lanacheng Biotechnology Co., Ltd. (referred to as "Lanacheng"), has received the "Production License for Radioactive Drugs" from the Shandong Provincial Drug Administration. This license is expected to have no significant impact on the company's current performance, and the fluorine-18 labeled peptide injection will be commercially produced after obtaining the drug listing approval number [1]. Group 1 - Dongcheng Pharmaceutical's subsidiary Lanacheng has received a production license for radioactive drugs [1] - The production license is anticipated to not significantly affect the current performance of Dongcheng Pharmaceutical [1] - The fluorine-18 labeled peptide injection will be available for commercial production following the drug listing approval [1]